SAG
AQST icon

SageView Advisory Group’s Aquestive Therapeutics AQST Stock Holding History

SageView Advisory Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-553
Closed -$3.57K – 684
2025
Q4 		$3.57K Buy
+553
New +$3.45K ﹤0.01% 2053

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SageView Advisory Group's AQST Position: Q1 2026 in Review

SageView Advisory Group sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 553 shares — an estimated $3.57K sold.

SageView Advisory Group first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $3.57K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • SageView Advisory Group reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 553 Aquestive Therapeutics shares in Q1 2026, an estimated $3.57K.
  • SageView Advisory Group first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Aquestive Therapeutics position peaked at $3.57K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.